LYEL Earnings Date: Nov 10, 2026 (Estimated) — Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is LYEL's next earnings date?
Lyell Immunopharma, Inc. (LYEL) is expected to report earnings on Tuesday, November 10, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$2.06 on revenue of $4,600.
How did LYEL do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Lyell Immunopharma, Inc. posted EPS of -$1.92 versus the -$1.90 estimate, a miss of 4.0%. Revenue was $4,000 against a $3,625 estimate. The stock's 1-day post-earnings move was +3.5%.
How much does LYEL stock move after earnings?
LYEL beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.1% (up or down) in the day after earnings.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.90 | -1.92 | +4.00% | $4,000 | ❌ Miss | +3.52% | -3.31% | +1.13% |
| 2026-05-06 | Q1 2026 | -2.45 | -1.10 | +55.10% | $2,000 | ✅ Beat | -3.79% | -7.72% | -42.59% |
| 2026-03-12 | Q4 2025 | -2.20 | -7.68 | -249.09% | $6,000 | ❌ Miss | -14.23% | -16.17% | +0.10% |
| 2025-11-12 | Q3 2025 | -2.71 | -2.13 | +21.40% | $15,000 | ✅ Beat | -1.25% | -2.33% | +95.46% |
| 2025-08-12 | Q2 2025 | -2.90 | -2.89 | +0.34% | $8,000 | ✅ Beat | +2.46% | +2.46% | +25.83% |
| 2025-03-11 | Q4 2024 | -0.13 | -0.16 | -23.08% | $11,000 | ❌ Miss | +0.90% | -27.32% | -33.67% |
| 2024-11-07 | Q3 2024 | -0.20 | -0.14 | +30.00% | $34,000 | ✅ Beat | +0.00% | -9.84% | -26.23% |
| 2024-08-07 | Q2 2024 | -0.20 | -0.15 | +25.00% | $13,000 | ✅ Beat | +6.38% | -14.89% | -17.02% |
Showing last 8 quarters.